act1 peptide aCT1 - acein-peptide-for-sale aCT1 peptide Understanding the Multifaceted Role of ACT1 Peptide in Biological Processes

difference-entre-peptide-et-polypeptide The ACT1 peptide, a synthetic peptide mimetic of the carboxyl-terminal domain of connexin 43 (Cx43), has emerged as a molecule of significant interest due to its diverse biological activities. Research highlights its potential in wound healing, regenerative repair, and even in modulating cellular communication relevant to cancer and viral infections. This exploration delves into the mechanisms, applications, and ongoing research surrounding aCT1 peptide, drawing upon a wealth of scientific findings.作者：P Chen·2009·被引用次数：1—Results: : Initial corneal wound area as determined by fluorescein labeling at 0 hours: for untreated, controlpeptideandACT1-treated rats was 9.7±0.3 (pixels) ...

At its core, the ACT1 peptide functions by targeting and stabilizing the activity of endogenous Cx43Act1 peptideis applicable as a control peptide for blocking antibody binding in Western blotting. References & Citations. 1. Leonardi A, Chariot A, Claudio E, .... Cx43 is a crucial transmembrane protein that forms gap junctions, facilitating intercellular communicationACT1 | SGD. The ACT1 peptide specifically interacts with Cx43's binding partners, notably ZO-1 (Zonula Occludens-1), a cytoplasmic protein that plays a vital role in maintaining epithelial cell polarity and integrity. By competitively inhibiting the interaction between Cx43 and ZO-1, or by stabilizing Cx43 at gap junction sites, ACT1 can modulate cellular signaling pathways. This interaction is central to many of its observed effectsACT-1 peptide: Uses, Interactions, Mechanism of Action.

One of the most extensively studied applications of ACT-1 peptide is in the realm of wound healing and skin regenerationaCT1is a mimeticpeptideof Connexin43 (Cx43), a transmembrane gap junction protein, which interacts with Cx43's binding partners, including tight junction .... Preclinical studies have demonstrated that ACT1 can significantly accelerate wound closure, enhance epidermal complexity, and reduce the formation of granulation tissueACT1is shown to accelerate wound closure, enhance epidermal complexity, reduce granulation tissue area and increase breaking strength and extensibility of skin .... Furthermore, it has been shown to increase the breaking strength and extensibility of skin, suggesting a role in promoting more robust and organized tissue repair.2014年8月21日—ACT1works by binding to the ZO1 protein, preventing it from connecting to another protein known as connexin 43. It's the first connexin- ... This regenerative capacity has led to investigations into its use for chronic wounds, such as diabetic foot ulcers (DFUs), where impaired healing is a significant clinical challengeA Synthetic Peptide ACT 1 Enhances Corneal Wound Healing. The topical administration of aCT1 peptide has shown promise in augmenting the reepithelialization of such chronic wounds.

Beyond skin repair, the influence of ACT1 peptide extends to its potential in combating viral infections. Research has indicated that aCT1 can reduce the severity of SARS-CoV-2-induced lung injury. This suggests a broader anti-inflammatory or protective role that may be leveraged against other inflammatory conditions mediated by Cx43 signaling.

The ACT1 peptide also holds promise in oncological research.The second row (B) is representative of nine wounds receiving apeptidecorresponding to the 16 amino acid antennapedia sequence (blue arrow) ofACT1. This ... Its ability to modulate Cx43 and gap junction intercellular communication (GJIC) is being explored for its anti-cancer activity.First clinical trial for new skin wound-healing compound is ... Studies suggest that aCT1 can promote GJIC and Cx43 protein stabilization, potentially impacting the behavior of cancer cells, particularly in HER2+ breast cancer. Furthermore, ACT1 has been shown to enhance the efficacy of targeted inhibitors like tamoxifen and lapatinib, suggesting a synergistic therapeutic strategy in cancer treatmentLoop Decoy Peptide Blocks the Interaction Between Act1 and .... The identification of a specific CC’ loop region within Act1 as critical for receptor-adaptor protein interactions further refines our understanding of its mechanistic pathways in cellular signaling and cancer biology作者：CL Grek·2015·被引用次数：69—Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1)peptideenhances the activity of the targeted inhibitors, tamoxifen and lapatinib ....

From a pharmacological standpoint, ACT1 is described as a low molecular weight synthetic peptide fragmentACT1is shown to accelerate wound closure, enhance epidermal complexity, reduce granulation tissue area and increase breaking strength and extensibility of skin .... Its development has been associated with entities like Xequel Bio (formerly FirstString Research). The peptide itself is a 25 amino acid synthetic peptide containing the carboxy-terminal PDZ binding domain of Cx43. For research purposes, ACT1 is available as a lyophilized powder with high purity, often tested via HPLC. It can also be utilized as a control peptide for blocking antibody binding in techniques like Western blotting.

The scientific literature references various forms and related peptides, including aCT1 peptide, ACT-1 peptide, and Act1 peptide, all referring to the same or closely related connexin 43 mimetic作者：CL Grek·2015·被引用次数：125—Treatment protocols that incorporateACT1may present a therapeutic strategy that safely augments the reepithelialization of chronic DFUs.. Research using ACT 1 extends to various cell lines, including canine melanoma cells (TLM1), and animal models, such as rats for corneal wound healing studies. The peptide ACT1's ability to influence corneal wound healing has been demonstrated by a reduction in initial corneal wound area in treated subjects.

In summary, the ACT1 peptide represents a compelling area of scientific inquiry. Its ability to modulate Cx43 function has far-reaching implications for regenerative medicine, particularly in wound healing and skin repair作者：CL Grek·2015·被引用次数：125—Treatment protocols that incorporateACT1may present a therapeutic strategy that safely augments the reepithelialization of chronic DFUs.. Ongoing research continues to uncover its potential in antiviral therapies and as an adjunct in cancer treatment, solidifying its status as a versatile and promising biomolecule in the field of peptides.